Accentia Biopharmaceuticals, Inc. (NASDAQOTH:ABPI)

CAPS Rating: No stars

A biopharmaceutical company focused on the development & commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease &, through its publicly-traded subsidiary, Biovest International Inc., oncology.

Results 1 - 5 of 5


Member Avatar binx007 (38.76) Submitted: 3/3/2008 5:09:26 PM : Outperform Start Price: $2.43 ABPI Score: -159.02

I am bullish on this spec play. I think they are going to have some good results for us this month and after that, the SKY is the limit. Hold on to your boot straps. The down side is so small it is hard not to love the opportunity to win BIG here.


Member Avatar maggioli (64.57) Submitted: 1/7/2008 9:00:50 PM : Outperform Start Price: $2.60 ABPI Score: -151.34

The CEO has just given a resounding forward statement, if you wait to long you could miss the boat. If they get FDA approval on all three phase three products the sky is the limit. Buy now or cry later.


Member Avatar gingerlade (< 20) Submitted: 12/28/2007 8:09:34 PM : Outperform Start Price: $3.14 ABPI Score: -146.18

The company has a few blockbuster biopharmaceuticals in the pipeline awaiting

fast track and FDA approval...SinuNase (BDSI)and

Revimmune for 80 autoimmune diseases focusing

for now on relapse-remit MS....and a vaccine

for Hodgkins Lymphoma and a Biovac machine

to administer this on fast track....the

vaccine is being put out by BVTI a subsidiary

of APBI....Great potential this stock....of

course this is my humble always

one must do their own research into this...

but once you will be flabbergasted

at the potential of these multi-billion

dollar blockbusters if they pass FDA approval...Awesome promise....


Member Avatar myersfield (< 20) Submitted: 9/20/2007 2:36:09 PM : Outperform Start Price: $2.68 ABPI Score: -142.34

ABPI is in 2 phase 3 trials and I believe in success.


Member Avatar altrue1090 (59.40) Submitted: 10/28/2006 3:16:21 AM : Outperform Start Price: $3.17 ABPI Score: -159.15

Excellent results in hard-to-treat recurrent non-Hodgkins Lymphoma trial make this company a prime buyout candidate from big pharma.

Results 1 - 5 of 5

Featured Broker Partners